Mutation screening of the CDKN2A promoter in melanoma families

Genes Chromosomes and Cancer

Volumn 28, Issue 1, 2000, Pages 45-57

  Harland, Mark ^a   Holland, Elizabeth A ^b   Ghiorzo, Paola ^c   Mantelli, Michela ^c   Bianchi Scarrà, Giovanna ^c   Goldstein, Alisa M ^d   Tucker, Margaret A ^d   Ponder, Bruce A J ^e   Mann, Graham J ^b   Bishop, D Timothy ^a   Bishop, Julia Newton ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEGREGATION; GENE SEQUENCE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; MELANOMA; PRIORITY JOURNAL; PROMOTER REGION;

EID: 6744226360     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.0.CO;2-F     Document Type: Article

References (48)

1. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. 1996. The p16 cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483.
2. Bates S, Phillips AC, Clark PA, Statt F, Peters G, Ludwig RL, Vousden KH. 1998. p14ARF links the tumour suppressors RB and p53. Nature 395:124-125.
3. Bird A. 1992. The essentials of DNA methylation. Cell 70:5-8.
4. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade OI, Diaz MO, Kwiatkowski DJ, Piepcorn MW, Zone JJ, Skolnick MH. 1992. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148-1152.
5. Cannon-Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, Jost M, Tran TD, Nguyen K, Kamb A, Weaver-Feldhaus J, Meyer LJ, Zone JJ, Skolnick MH. 1994. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 23:265-268.
6. Ciotti P, Stringini P, Bianchi-Scarrà G, Ligurian Skin Tumor Study Group. 1996. Familial melanoma and pancreatic cancer. N Engl J Med 334:469-470.
7. Clarke DJ, Moghrabi N, Monaghan G, Cassidy A, Boxer M, Hume R, Burchell B. 1997. Genetic defects of the UDP-glucuronosyl-transferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clinica Chimica Acta 266:63-74.
8. Costello JF, Berger MS, Su Huang H-J, Cavence WK. 1996. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410.
9. Dracopoli NC, Fountain JW. 1996. CDKN2 mutations in melanoma. Cancer Surveys 26:115-132.
10. Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Oakes S, Wilson C, Stratton M, Peto J, Easton D, Clayton D, Ponder BA. 1997. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet 6:285-289.
11. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. 1996. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Nat Acad Sci USA 93:8541-8545.
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenior G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck RR, Tonin P, Neuhausen S, Barkadottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Hedman MA, Consortium BCL. 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689.
13. Foulkes W, Flanders TY, Pollock PM, Hayward NK. 1997. The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20.
14. INK4/MST1 and p19 in human cancer cell lines. Int J Cancer 68:605-611.
15. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark Jr WH, Tucker MA. 1994. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic-heterogeneity. Am J Hum Genet 54:489-496.
16. Gruis NA, Sandkuijl LA, Weber JL, van der Zee A, Borgstein AM, Bergman W, Frants RR. 1993. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 3:271-277.
17. CDKN2 expression and its implication for cell immortalization and senescence. Mol Cell Biol 16:859-867.
18. Harland MH, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf A-M, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Newton Bishop J. 1997. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061-2067.
19. Hayward NK. 1996. The current situation with regard to human melanoma and genetic inferences. Curr Opin Oncol 8:136-142.
20. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
21. Holland KA, Beaton SC, Becker TM, Grulet OMC, Peters BA, Rizos H, Kefford RF, Mann GJ. 1995. Analysis of the p16 gene, CDKN2, in Australian melanoma kindreds. Oncogene 11:2289-2294.
22. Holland EA, Schmidt H, Kefford RF, Mann GJ. 1999. CDKN2A (p16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25:339-348.
23. Kozak M. 1996. Interpreting cDNA sequences: some insights from studies on translation. Mammalian Genome 7:563-574.
24. Kruglyak L. 1999a. Genetic isolates: separate but equal? Proc Natl Acad Sci USA 96: 1170-1172.
25. Kruglyak L. 1999b. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 22:139-144.
26. Kumar R, Rozell BL, Louhelainen J, Hemminki K. 1998. Mutations in the CDKN2A (p16INK4a) gene in microdissectcd sporadic primary melanomas. Int J Cancer 75:193-198.
27. Liggett WHJ, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D. 1996. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56:4119-4123.
28. Liggett WHJ, Sidransky D, 1998. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16:1197-1206.
29. ARF. Genes Chromosomes Cancer 19:52-54.
30. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. 1999. Mutation of the CDKN2A5′ LTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128-132.
31. MacGeoch C, Newton-Bishop JA, Bataille V, Bishop DT, Frischauf A-M, Meloni R, Cuzick J, Pinney E, Spurr NK. 1994. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 3:2195-2200.
32. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K, Satodate R. 1996. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 56:3875-3878.
33. Mann GJ, Holland EA, Becker TM, Grulet OMC, Rizos H, Kefford RF. 1997. Mutation and linkage analysis of cdkn2a and cdk4 in 119 Australian melanoma kindreds. Am J Hum Genet 61:397.
34. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. 1995. A novel p16INK4A transcript. Cancer Res 55:2995-2997.
35. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson K, Burger PC, Baylin SB, Sidransky D. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKB2/MTS1 in human cancers. Nat Med 1:686-692.
36. Newton Bishop JA, Hurland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BAJ, Cuzick J, Selby P, Bishop DT. 1999 Mutation testing in melanoma families INK4A, CDK4 and INK4D. Br J Cancer 80:295-300.
37. Peeters AV, Kotze MJ, Scholtz CL, De Waal LF, Rubinsztein DC, Coetzee GA, Zuliani G, Streiff R, Liu J, van der Westhuyzen DR. 1998. A 3-basepair deletion in repeat 1 of the LDL receptor promoter reduces transcriptional activity in a South African Pedigree. J Lipid Res 39:1021-1024.
38. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S. 1999. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 59:455-461.
39. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative-reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
40. p19ARF. Proc Natl Acad Sci USA 94:669-673.
41. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ. 1995a. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509.
42. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen MK, Rollins RJ, 1995b. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55:6200-6209.
43. Soufir N, Avril M-F, Chompret A, Demenais F, Bumbled J, Spatz A, Stoppa-Lyonnet D, French Familial Melanoma Study Group, Benard J, Bressac-de Paillerets B. 1998. Prevalence of pin and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-216.
44. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A. 1995. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994.
45. van der Velden PA, Sankuijl LA, Bergman W, Mille ETM, Frants RR, Gruis NA. 1999. A locus linked to p16 modified melanoma risk in Dutch familial atypical multiple mole melanoma (FAMM) syndrome families. Genome Res 9:575-580.
46. Walker GJ, Nancarrow DJ, Palmer JM, Walters MK, Hayward NK, 1994. Haplotype analysis limits the position of the familial melanoma locus on 9p to the D9S169-D9S156 interval. Melanoma Res 4:29-34.
47. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. 1998. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-63.
48. INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99.